enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.…
EnGene Therapeutics (ENGN) Stock Gets Fair Value Boost After Analyst Views On LEGEND Data
enGene Therapeutics (NASDAQ: ENGN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 81 employees.
The shares were at 1.740 USD on 20 November 2026, down 80.0% over 52 weeks. Its 52-week range is 1.400 USD to 12.25 USD: the price is 85.8% below the high and 24.3% above the low.
Its market capitalisation is 116.61M USD.
enGene Therapeutics reports return on equity of -69.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 233.05M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 7 analysts cover the stock, with an average rating of Buy; their mean price target of 4.286 USD is 146.3% above the current price. The next earnings report is expected on 22 December 2026.